Market Research Report
4 Reports Bundle: Immuno-Oncology - Inhibitory and Stimulatory Immunomodulators
|Published by||La Merie Publishing||Product code||408112|
|Published||Content info||455 Pages
Delivery time: 1-2 business days
|4 Reports Bundle: Immuno-Oncology - Inhibitory and Stimulatory Immunomodulators|
|Published: July 26, 2018||Content info: 455 Pages||
This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSC).
Each of the four reports can be obtained individually, but the package of the four reports provides a 40% discount on the regular prices:
Targets of Immunomodulators are inhibitory as well as stimulatory immune checkpoints and from the tumor microenvironment:
More than 190 unique molecules (many antibodies) targeting inhibitory and stimulatory immunomodulators are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. This number has more than doubled since December 2016.
The reports include compilations of currently active projects in research and development of immunomodulators in immuno-oncology. In addition, each report lists company-specific R&D pipelines of cancer immunomodulators. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.